CDEK
← All organizations

Merz

For profitContributed to NME

Also known as: LLC Merz Pharma, Russia | MERZ | Merz Aesthetics | Merz Aesthetics GmbH | Merz Aesthetics Inc. | Merz North America | Merz North America, Inc. | Merz Pharmaceutical, LLC | Merz Pharmaceuticals | Merz Pharmaceuticals GmbH | Merz Pharmaceuticals GmbH c/o Merz Pharmaceuticals LLC | Merz Pharmaceuticals, LLC | MERZ PHARMS | Merz Therapeutics | Merz Therapeutics GmbH

Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 4

First clinical trial

Oct 1, 2005

First marketed drug

Jul 11, 1985

First NDA

Jul 30, 2010

Last known activity

Oct 1, 2025

Timeline

1900s

  1. Jan 1, 1908

    Merz— Founded

1990s

  1. Apr 3, 1995

    Mayrand— Acquired

2010s

  1. Jan 1, 2010

    BioForm Medical— Acquired

  2. Jul 28, 2010

    glycopyrronium— NDA Secondary Org

  3. Jul 30, 2010

    incobotulinumtoxinA— NDA Organization

  4. Jan 1, 2013

    Neocutis S.A.— Acquired

  5. Jan 1, 2014

    Ulthera— Acquired

  6. Dec 21, 2018

    levodopa— Marketing Organization

Drugs by trial phase (23 distinct, 111 trials)

Phase 3 (2 own, 0 via acquisition)

Phase 1 (1 own, 0 via acquisition)

Indications

Studied for

Marketed drugs (5)

Subsidiaries (4 direct, 4 total across the full acquisition tree)

Recent trials (50)

Details

Founded
Frankfurt am Main, DE Jan 1, 1908
First NDA
Jul 30, 2010
Last known activity
Oct 1, 2025